What other stocks do shareholders of Emerald Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emerald Bioscience investors own include Fulcrum Therapeutics (FULC) , VIVUS (VVUS) , Charlotte's Web (CWBHF) , Akero Therapeutics (AKRO) , CymaBay Therapeutics (CBAY) , Cognex (CGNX) , Cumberland Pharmaceuticals (CPIX) , Corbus Pharmaceuticals (CRBP) and Editas Medicine (EDIT) .

How do I buy shares of Emerald Bioscience?

Shares of EMBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:EMBI

Emerald Bioscience (EMBI) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free EMBI Stock Alerts

Compare

Today's Range: N/A
50-Day Range: $0.09
▼
$17.75
52-Week Range: N/A

Volume: 6.96 million shs
Average Volume: 14.24 million shs
Market Capitalization: $24.13 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Emerald Bioscience alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Emerald Bioscience Stock (OTCMKTS:EMBI)

Emerald Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics for unmet medical needs worldwide. The company's lead product candidate is NB1111, which is in preclinical trials for the treatment of glaucoma. It is also developing NB2222, a product candidate in preclinical trials for use in the treatment of various eye diseases, including uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy; and NB3111, a cannabinoid cocktail in testing for use as an anti-infective agent against various strains of antibiotic resistant bacteria, including methicillin-resistant Staphylococcus aureus. The company was formerly known as Nemus Bioscience, Inc. and changed its name to Emerald Bioscience, Inc. in March 2019. Emerald Bioscience, Inc. was founded in 2012 and is based in San Diego, California.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

EMBI Stock News Headlines

April 16, 2024 | benzinga.com

Cannabis Bioscience Stock (OTC:CBIH), Quotes and News Summary

April 10, 2024 | americanbankingnews.com

Emerald Bioscience (OTCMKTS:EMBI) Reaches New 1-Year High at $9.23

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 21, 2024 | finance.yahoo.com

Daré Bioscience, Inc. (DARE)

January 17, 2024 | wsj.com

Star Lake Bioscience Co. Ltd. Guangdong Zhaoqing A

November 15, 2023 | lse.co.uk

Bnp Paribas Easy Jpm Esg Embi Global Diversified Composite Ucits Etf H Eur Cap Share Price (EMBH.PA)

September 6, 2023 | bizjournals.com

Construction starts on $55M senior living project in Redmond

February 21, 2023 | duluthnewstribune.com

Duluth takes less aggressive stance against emerald ash borers, prepares to cut

April 19, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

July 11, 2022 | finance.yahoo.com

Emerald Health Therapeutics, Inc. Reports 2022 Q1 Results

See More Headlines

Receive EMBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emerald Bioscience and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: N/A
Sub-Industry: N/A
Current Symbol: OTCMKTS:EMBI
CUSIP: N/A
CIK: N/A
Web: www.emeraldbio.life
Phone: 949-336-3443
Fax: N/A
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $1.05 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: -347.62%

Debt

Debt-to-Equity Ratio: 0.43
Current Ratio: 3.59
Quick Ratio: 3.59

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 268,074,000
Free Float: N/A
Market Cap: $24.13 million
Optionable: Not Optionable
Beta: 0.43

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Punit S. Dhillon B.A. (Age 40)
BA, Exec. Chairman & CEO
Comp: $65k
Mr. Richard Janney
Interim Principal Accounting Officer
Ms. Elena Traistaru (Age 61)
Company Sec.

Key Competitors

View All Competitors

EMBI Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Emerald Bioscience own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Emerald Bioscience investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Charlotte's Web (CWBHF), Akero Therapeutics (AKRO), CymaBay Therapeutics (CBAY), Cognex (CGNX), Cumberland Pharmaceuticals (CPIX), Corbus Pharmaceuticals (CRBP) and Editas Medicine (EDIT).
How do I buy shares of Emerald Bioscience?: Shares of EMBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:EMBI) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Emerald Bioscience (EMBI) Stock Price, News & Analysis

About Emerald Bioscience Stock (OTCMKTS:EMBI)

EMBI Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

EMBI Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info